SGMO Sangamo Therapeutics Inc.

11.06
-0.01  -0%
Previous Close 11.07
Open 11.11
Price To Book 2.97
Market Cap 1129147065
Shares 102,092,863
Volume 1,301,480
Short Ratio
Av. Daily Volume 2,026,337

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 19511534
  2. CT ORDER - Confidential treatment order 181213318
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170540
  4. 8-K - Current report 181170154
  5. 8-K - Current report 181163325

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented after dose escalation is complete.
SB-525 cDNA gene therapy
Hemophilia A
Phase 1/2 early data due 2019.
ST-400
beta-thalassemia
Phase 1/2 preliminary safety and biochemical measurements due at WORLDSymposium, February 7, 2019 11:15am.
SB-318
MPS Type 1
Phase 1/2 data due 2019.
SB-FIX
Hemophilia B
Biochemical and safety data due at the 2019 WORLDSymposium - February 7, 2019. 11am ET (MINOR CATALYST). More significant ERT withdrawal data due later in 2019.
SB-913 - CHAMPIONS
MPS Type 2

Latest News

  1. Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development
  2. Here's How I Would Handle Speculative Sangamo Therapeutics
  3. Jim Cramer Advises His Viewers On Brink's, Medtronic And More
  4. Cramer's lightning round: 'I'm not endorsing' Fiat Chrysler's stock anymore
  5. Top Picks 2019- Sangamo Therapeutics SGMO
  6. Portfolios Making Up For Lost Time
  7. Sangamo Therapeutics To Present at the 37th Annual J.P. Morgan Healthcare Conference
  8. Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019
  9. How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
  10. A Financial Overview of Sangamo Therapeutics in December 2018
  11. How Analysts View Sangamo Therapeutics in December
  12. Biotech markets could be ‘very promising’ in 2019
  13. Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
  14. Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
  15. Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
  16. Gilead's (GILD) Harvoni and Descovy Get Approval in China
  17. Gilead (GILD) Announces Data on CAR T Therapy Candidate
  18. Is Sangamo Therapeutics Inc (NASDAQ:SGMO) A Financially Sound Company?
  19. Sangamo Announces Completion Of TxCell Acquisition
  20. Better Buy: Editas Medicine vs. Sangamo Therapeutics

SEC Filings

  1. 8-K/A [Amend] - Current report 19511534
  2. CT ORDER - Confidential treatment order 181213318
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170540
  4. 8-K - Current report 181170154
  5. 8-K - Current report 181163325
  6. 8-K - Current report 181097658
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001923
  8. 8-K - Current report 181001734
  9. 8-K - Current report 18963537
  10. 8-K - Current report 18926408